Diakonos Oncology
Diakonos Oncology is a clinical-stage biotechnology company focused on developing groundbreaking immunotherapy treatments for difficult-to-treat cancers. With FDA Fast Track designation, they are advancing innovative dendritic cell vaccines, such as DOC1021, to improve patient outcomes in cancers like glioblastoma and pancreatic adenocarcinoma. Their research leverages a novel understanding of dendritic cell mechanisms to activate powerful immune responses, aiming to address unmet medical needs in oncology.
Industries
Nr. of Employees
small (1-50)
Products
Autologous double-loaded dendritic cell immunotherapy
An investigational autologous dendritic cell therapy produced by loading patient-derived tumor mRNA intracellularly and tumor lysate extracellularly to present overlapping MHC class I and II epitopes and induce Th1/cytotoxic T-cell responses for solid tumors.
DOC1021
DOC1021 is a multi-step process that harnesses the patient’s natural immune response using dendritic cells stimulated by homologous antigenic loading to target and eliminate cancer cells.
Autologous Dendritic Cells Pancreatic Cancer Therapy
An investigational delivery of autologous Dendritic Cells (DCs) to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.
Diakonos Dendritic Cell Vaccine
An investigational personalized cancer immunotherapy utilizing a proprietary 'double-loading' mechanism of tumor mRNA and lysate onto dendritic cells to stimulate a robust Th1 anti-viral immune response and killer T cell activation.
Autologous double-loaded dendritic cell immunotherapy
An investigational autologous dendritic cell therapy produced by loading patient-derived tumor mRNA intracellularly and tumor lysate extracellularly to present overlapping MHC class I and II epitopes and induce Th1/cytotoxic T-cell responses for solid tumors.
DOC1021
DOC1021 is a multi-step process that harnesses the patient’s natural immune response using dendritic cells stimulated by homologous antigenic loading to target and eliminate cancer cells.
Autologous Dendritic Cells Pancreatic Cancer Therapy
An investigational delivery of autologous Dendritic Cells (DCs) to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.
Diakonos Dendritic Cell Vaccine
An investigational personalized cancer immunotherapy utilizing a proprietary 'double-loading' mechanism of tumor mRNA and lysate onto dendritic cells to stimulate a robust Th1 anti-viral immune response and killer T cell activation.
Services
Design and execution of Phase 1 and randomized multi-center Phase 2 oncology trials at academic and clinical partner sites.
Evaluation and potential initiation of expanded access pathways for patients who do not qualify for clinical trials of investigational cell therapy.
Collaborative preclinical and translational research with academic institutions to advance mechanistic understanding and validate therapeutic approaches.
Design and execution of Phase 1 and randomized multi-center Phase 2 oncology trials at academic and clinical partner sites.
Evaluation and potential initiation of expanded access pathways for patients who do not qualify for clinical trials of investigational cell therapy.
Collaborative preclinical and translational research with academic institutions to advance mechanistic understanding and validate therapeutic approaches.
Expertise Areas
- Dendritic cell vaccine development
- Autologous cell therapy manufacturing and processing
- Oncology clinical trial design and execution
- Immunology of Th1 polarization and T-cell activation
Key Technologies
- Dendritic cell vaccine platform
- Autologous tumor mRNA isolation and amplification
- Electroporation-mediated mRNA delivery
- Tumor lysate preparation for ex vivo antigen presentation